Clinical trial PIVeR
A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposide (PIVeR)
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | LYSA LYmphoma |
EudraCT Identifier | 2017-000719-17 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03458260 |
Inclusion criteria | -DLBCL CD20 +de novo or transformed from low grade NHL or follicular lymphoma grade 3b -relapsed or refractory : Patients eligible for ASCT who failed to achieve a CR after at least one salvage therapy Or patients in first relapse after ASCTOr patients |
Last update |